CN108434535A - A kind of preparation method inhibiting hyperblastosis type coating bracket material - Google Patents
A kind of preparation method inhibiting hyperblastosis type coating bracket material Download PDFInfo
- Publication number
- CN108434535A CN108434535A CN201810396947.7A CN201810396947A CN108434535A CN 108434535 A CN108434535 A CN 108434535A CN 201810396947 A CN201810396947 A CN 201810396947A CN 108434535 A CN108434535 A CN 108434535A
- Authority
- CN
- China
- Prior art keywords
- parts
- hyperblastosis
- coating
- type coating
- stirred
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/08—Materials for coatings
- A61L31/10—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/148—Materials at least partially resorbable by the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/602—Type of release, e.g. controlled, sustained, slow
- A61L2300/604—Biodegradation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/606—Coatings
Landscapes
- Health & Medical Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Surgery (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Materials For Medical Uses (AREA)
Abstract
The present invention relates to a kind of preparation methods inhibiting hyperblastosis type coating bracket material, belong to medical material tech field.Technical solution of the present invention passes through using glucan as modifier,Since hydrophilic glucan can absorb large quantity of moisture in aqueous solution,Constitute the polymer brush to wave in aqueous solution,It has larger hydrodynamics volume,Physical barrier is generated around the drug of its modification,Being in direct contact for protein etc. and material can be reduced,Protein adherence and denaturation are prevented with anti-adhesion effect,To effectively inhibit the phenomenon that the load of coating bracket surface texture and hyperplasia,And technical solution of the present invention by matrix resin of polylactic acid by being coated,Increase the binding force of polymer and metallic matrix,To meet the requirement of bracket coating,Prepared polymer coating has preferable biological stability,Material implanted requirement is reached,Coating has the function of slow releasing pharmaceutical,Compound existing coating bracket degradable demand in human body.
Description
Technical field
The present invention relates to a kind of preparation methods inhibiting hyperblastosis type coating bracket material, belong to medical material technology neck
Domain.
Background technology
The problem of In-stent Restenosis, is concerned, and people go deep into a variety of drugs for stent restenosis
Research, such as taxol, rapamycin, inhibitors of cyclooxygenases, but often zoopery effectively and clinical efficacy is little, master
The release targeting the reason is that the therapy of this Formulations for systemic administration suffers for want of medical supplies is wanted, local drug concentration is insufficient or efficacy time mistake
It is short, it is unable to reach satisfactory therapeutic effect.Recent study shows that discharging blood concentration by topical remedy can reach
10 times or more of oral concentration, curative effect is much better than traditional administering mode.Local administration can be by carrying Targeting delivery function
Wrap up in medicine micro-capsule realization, drug coat can also be implanted together on holder, the latter can be such that local organization reaches
To the effective concentration of drug therapy, and the drug concentration in systemic blood is extremely low, and can maintain longer administration time, therefore imitates
Fruit is more preferably.
The carrier material of drug stent is mostly nondegradable, polymer material, such as polybutyl methacrylate now;
The inlay and break copolymer etc. of polyvinyl acetate polycarboxylated styrene-isobutene-hydroxy styrenes.By the corruption of prolonged human body
Erosion, material itself can aging, fall off, fritter will be formed in vascular tissue, so as to cause the adverse reaction in late period.And
If using biodegradable material as drug carrier material, it is possible to reduce the appearance of late period adverse reaction.
Therefore, a kind of ideal stent system, current main research direction are developed.But restenosis is mainly due to holder in frame
Implantation, migration, cause blood vessel endothelium injury, and smooth muscle cell and extracellular matrix proliferation is stimulated to promote neo-intimal hyperplasia,
Typically occur in holder and arterial blood tube wall contact position.Platelet adhesion reaction and activation cell proliferation also have important influence,
Blood platelet is in its surface aggregation and activation after being implanted into holder, and secreting a large amount of various cell factors leads to thrombosis, thereafter greatly
The leucocyte of amount is assembled in vascular injury site, and secrete cytokines have an impact the tissue of healing.Inflammatory response refers to blood
Pipe smooth muscle cell, which is largely migrated to damage location, occurs breeder reaction, leads to a large amount of hyperplasia of new intima, due in new life
The formation of film causes the reconstruct of vascular wall so as to cause in-stent restenosis.So how to prepare one kind having degradability simultaneously
Effectively inhibit the coating bracket material of hyperblastosis necessary.
Invention content
The technical problems to be solved by the invention：It is not degradable for existing coating bracket material and tissue can not be inhibited again
Raw problem provides a kind of preparation method inhibiting hyperblastosis type coating bracket material.
In order to solve the above technical problems, the technical solution adopted by the present invention is：
（1）It counts in parts by weight, weighs 45~50 parts of dimethyl sulfoxide (DMSO)s, 3~5 parts of glucans, 1~2 part of salicylic acid and 0.1 respectively
~0.5 part of potassium hydroxide is placed in beaker, is stirred simultaneously oil bath heating, obtains mixed liquor and standing is cooled to room temperature, collect cold
But reaction solution；
（2）Cooling reaction solution is set into rotary evaporation, liquid and by volume 1 must be rotated:8, revolving liquid is added in ethyl acetate,
It is stirred and still aging, centrifuges, collect lower sediment and vacuum freeze drying, grind to obtain modified powder；
（3）Count in parts by weight, respectively weigh 45~50 parts of 5% dextran solutions of mass fraction, 6~8 parts of fibroin albumens, 10~
15 parts of 8% chitosan solutions of mass fraction are placed in conical flask and are stirred, and obtain mixed liquor and freezing processing, obtain lyophilized products
And wash, vacuum freeze drying is simultaneously ground, and obtains matrix powder；
（4）It counts in parts by weight, weighs 45~50 parts of matrix powders, 10~15 parts of particles of polylactic acid, 6~8 parts of modified powder respectively
In end, 25~30 parts of dichloromethane and 25~30 parts of ethyl acetate, it is stirred juxtaposition and stands at room temperature, obtain spray coating liquor, it will
Spray coating liquor is placed in spray equipment, spray treatment, stands solidification at room temperature, you can is prepared into and is inhibited hyperblastosis type coating branch
Frame material.
Step（2）The rotating evaporation temperature is 45~50 DEG C.
Step（3）The freezing processing temperature is -30~-20 DEG C.
Step（4）The spray treatment is that spray coating liquor is placed in spray equipment, and coutroi velocity is 0.03~0.05mL/
Min, ultrasonic power are 1.5~2.0W, are sprayed on Stainless steel 316 L holders.
Compared with other methods, advantageous effects are the present invention：
（1）Technical solution of the present invention is by using glucan as modifier, since hydrophilic glucan can absorb in aqueous solution
Large quantity of moisture constitutes the polymer brush to wave in aqueous solution, it has larger hydrodynamics volume, in the drug week of its modification
Enclose generation physical barrier, being in direct contact for protein etc. and material can be reduced, have anti-adhesion effect prevent protein adherence with
Denaturation, to effectively inhibit the phenomenon that the load of coating bracket surface texture and hyperplasia；
（2）Technical solution of the present invention by matrix resin of polylactic acid by being coated, after being coated to rack surface,
Rack surface carries the polymer coating of salicylic acid-glucan, increases the binding force of polymer and metallic matrix, to meet branch
The requirement of frame coating, prepared polymer coating have preferable biological stability, have reached material implanted
Requirement, coating have the function of slow releasing pharmaceutical, compound existing coating bracket degradable demand in human body.
Specific implementation mode
Count in parts by weight, respectively weigh 45~50 parts of dimethyl sulfoxide (DMSO)s, 3~5 parts of glucans, 1~2 part of salicylic acid and
0.1~0.5 part of potassium hydroxide is placed in beaker, is stirred and is placed in 6~8h of oil bath heating at 100~120 DEG C, obtains mixed liquor
And stand and be cooled to room temperature, the cooling reaction solution of collection is placed in rotation at 45~50 DEG C and is evaporated to the 1/5 of cooling reaction solution volume,
Liquid and by volume 1 must be rotated:8, revolving liquid is added in ethyl acetate, is stirred and still aging 6~8h, then
It is centrifuged under 1200~1500r/min, collects lower sediment and vacuum freeze drying, grind to obtain modified powder；By weight
Number meter, weighs 45~50 parts of 5% dextran solutions of mass fraction, 6~8 parts of fibroin albumens, 10~15 parts of mass fractions 8% respectively
Chitosan solution is placed in conical flask and is stirred, and obtains mixed liquor and is placed in 8~10h of freezing processing at -30~-20 DEG C,
Lyophilized products and with after acetone rinsing lyophilized products 3~5 times, vacuum freeze drying and grind again, obtain matrix powder；By weight
Measure number meter, respectively weigh 45~50 parts of matrix powders, 10~15 parts of particles of polylactic acid, 6~8 parts of modified powders, 25~30 parts
It in dichloromethane and 25~30 parts of ethyl acetate, is stirred juxtaposition and stands at room temperature, obtain spray coating liquor, spray coating liquor is placed in spray
In coating device, coutroi velocity is 0.03~0.05mL/min, and ultrasonic power is 1.5~2.0W, is sprayed into Stainless steel 316 L
On holder, at room temperature stand solidification 20~for 24 hours, you can be prepared into inhibit hyperblastosis type coating bracket material.
It counts in parts by weight, weighs 45 parts of dimethyl sulfoxide (DMSO)s, 3 parts of glucans, 1 part of salicylic acid and 0.1 part of hydroxide respectively
Potassium is placed in beaker, is stirred and is placed in oil bath heating 6h at 100 DEG C, obtains mixed liquor and standing is cooled to room temperature, collect cold
But reaction solution is placed in rotation at 45 DEG C and is evaporated to the 1/5 of cooling reaction solution volume, must rotate liquid and by volume 1:8, it will revolve
Steaming liquid is added in ethyl acetate, is stirred and still aging 6h, then is centrifuged at 1200r/min, and it is heavy to collect lower layer
Shallow lake and vacuum freeze drying, grind to obtain modified powder；It counts in parts by weight, it is molten to weigh 45 parts of 5% glucans of mass fraction respectively
Liquid, 6 parts of fibroin albumens, 10 parts of 8% chitosan solutions of mass fraction are placed in conical flask and are stirred, and obtain mixed liquor juxtaposition
The freezing processing 8h at -30 DEG C, obtains lyophilized products and with after acetone rinsing lyophilized products 3 times, again vacuum freeze drying and grounds travel
It is broken, obtain matrix powder；It counts in parts by weight, weighs 45 parts of matrix powders, 10 parts of particles of polylactic acid, 6 parts of modified powders, 25 respectively
In part dichloromethane and 25 parts of ethyl acetate, it is stirred juxtaposition and stands at room temperature, obtain spray coating liquor, spray coating liquor is placed in spraying
In device, coutroi velocity 0.03mL/min, ultrasonic power 1.5W are sprayed on Stainless steel 316 L holders, in room temperature
Lower standing cures 20h, you can is prepared into and inhibits hyperblastosis type coating bracket material.
It counts in parts by weight, weighs 47 parts of dimethyl sulfoxide (DMSO)s, 4 parts of glucans, 2 parts of salicylic acids and 0.2 part of hydroxide respectively
Potassium is placed in beaker, is stirred and is placed in oil bath heating 7h at 110 DEG C, obtains mixed liquor and standing is cooled to room temperature, collect cold
But reaction solution is placed in rotation at 47 DEG C and is evaporated to the 1/5 of cooling reaction solution volume, must rotate liquid and by volume 1:8, it will revolve
Steaming liquid is added in ethyl acetate, is stirred and still aging 7h, then is centrifuged at 1350r/min, and it is heavy to collect lower layer
Shallow lake and vacuum freeze drying, grind to obtain modified powder；It counts in parts by weight, it is molten to weigh 47 parts of 5% glucans of mass fraction respectively
Liquid, 7 parts of fibroin albumens, 12 parts of 8% chitosan solutions of mass fraction are placed in conical flask and are stirred, and obtain mixed liquor juxtaposition
The freezing processing 9h at -25 DEG C, obtains lyophilized products and with after acetone rinsing lyophilized products 4 times, again vacuum freeze drying and grounds travel
It is broken, obtain matrix powder；It counts in parts by weight, weighs 47 parts of matrix powders, 12 parts of particles of polylactic acid, 7 parts of modified powders, 27 respectively
In part dichloromethane and 27 parts of ethyl acetate, it is stirred juxtaposition and stands at room temperature, obtain spray coating liquor, spray coating liquor is placed in spraying
In device, coutroi velocity 0.04mL/min, ultrasonic power 1.7W are sprayed on Stainless steel 316 L holders, in room temperature
Lower standing cures 22h, you can is prepared into and inhibits hyperblastosis type coating bracket material.
It counts in parts by weight, weighs 50 parts of dimethyl sulfoxide (DMSO)s, 5 parts of glucans, 2 parts of salicylic acids and 0.5 part of hydroxide respectively
Potassium is placed in beaker, is stirred and is placed in 6~8h of oil bath heating at 120 DEG C, obtains mixed liquor and standing is cooled to room temperature, collect
Cooling reaction solution is placed in rotation at 50 DEG C and is evaporated to the 1/5 of cooling reaction solution volume, must rotate liquid and by volume 1:8, it will
Revolving liquid is added in ethyl acetate, is stirred and still aging 8h, then centrifuged at 1500r/min, and lower layer is collected
Simultaneously vacuum freeze drying is precipitated, modified powder is ground to obtain；It counts in parts by weight, weighs 50 parts of 5% glucans of mass fraction respectively
Solution, 8 parts of fibroin albumens, 15 parts of 8% chitosan solutions of mass fraction are placed in conical flask and are stirred, and obtain mixed liquor simultaneously
It is placed in 8~10h of freezing processing at -20 DEG C, obtains lyophilized products and with after acetone rinsing lyophilized products 5 times, vacuum freeze drying is simultaneously again
It grinds, obtains matrix powder；It counts in parts by weight, weighs 50 parts of matrix powders, 15 parts of particles of polylactic acid, 8 parts of modifications respectively
In powder, 30 parts of dichloromethane and 30 parts of ethyl acetate, it is stirred juxtaposition and stands at room temperature, obtain spray coating liquor, by spray coating liquor
It is placed in spray equipment, coutroi velocity 0.05mL/min, ultrasonic power 2.0W, is sprayed into Stainless steel 316 L holders
On, at room temperature stand solidification~for 24 hours, you can be prepared into inhibit hyperblastosis type coating bracket material.
Example 1,2,3 prepared by the present invention is tested for the property, specific test result is as follows shown in table table 1：
1 performance test table of table
As seen from the above table, the coating bracket material that prepared by the present invention has excellent inhibition hyperblastosis performance.
Claims (4)
1. a kind of preparation method inhibiting hyperblastosis type coating bracket material, it is characterised in that specifically preparation process is：
（1）It counts in parts by weight, weighs 45~50 parts of dimethyl sulfoxide (DMSO)s, 3~5 parts of glucans, 1~2 part of salicylic acid and 0.1 respectively
~0.5 part of potassium hydroxide is placed in beaker, is stirred simultaneously oil bath heating, obtains mixed liquor and standing is cooled to room temperature, collect cold
But reaction solution；
（2）Cooling reaction solution is set into rotary evaporation, liquid and by volume 1 must be rotated:8, revolving liquid is added in ethyl acetate,
It is stirred and still aging, centrifuges, collect lower sediment and vacuum freeze drying, grind to obtain modified powder；
（3）Count in parts by weight, respectively weigh 45~50 parts of 5% dextran solutions of mass fraction, 6~8 parts of fibroin albumens, 10~
15 parts of 8% chitosan solutions of mass fraction are placed in conical flask and are stirred, and obtain mixed liquor and freezing processing, obtain lyophilized products
And wash, vacuum freeze drying is simultaneously ground, and obtains matrix powder；
（4）It counts in parts by weight, weighs 45~50 parts of matrix powders, 10~15 parts of particles of polylactic acid, 6~8 parts of modified powder respectively
In end, 25~30 parts of dichloromethane and 25~30 parts of ethyl acetate, it is stirred juxtaposition and stands at room temperature, obtain spray coating liquor, it will
Spray coating liquor is placed in spray equipment, spray treatment, stands solidification at room temperature, you can is prepared into and is inhibited hyperblastosis type coating branch
Frame material.
2. a kind of preparation method inhibiting hyperblastosis type coating bracket material according to claim 1, it is characterised in that：
Step（2）The rotating evaporation temperature is 45~50 DEG C.
3. a kind of preparation method inhibiting hyperblastosis type coating bracket material according to claim 1, it is characterised in that：
Step（3）The freezing processing temperature is -30~-20 DEG C.
4. a kind of preparation method inhibiting hyperblastosis type coating bracket material according to claim 1, it is characterised in that：
Step（4）The spray treatment is that spray coating liquor is placed in spray equipment, and coutroi velocity is 0.03~0.05mL/min, ultrasound
Power is 1.5~2.0W, is sprayed on Stainless steel 316 L holders.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810396947.7A CN108434535A (en) | 2018-04-28 | 2018-04-28 | A kind of preparation method inhibiting hyperblastosis type coating bracket material |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810396947.7A CN108434535A (en) | 2018-04-28 | 2018-04-28 | A kind of preparation method inhibiting hyperblastosis type coating bracket material |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108434535A true CN108434535A (en) | 2018-08-24 |
Family
ID=63201940
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810396947.7A Pending CN108434535A (en) | 2018-04-28 | 2018-04-28 | A kind of preparation method inhibiting hyperblastosis type coating bracket material |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108434535A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1589162A (en) * | 2000-10-24 | 2005-03-02 | 博士伦公司 | Prevention of bacterial attachment to biomaterials by cationic polysaccharides |
| CN102008751A (en) * | 2010-11-24 | 2011-04-13 | 北京道淼浩博科技发展有限公司 | Biodegradable stent composite material and preparation method thereof |
| CN102772831A (en) * | 2012-08-20 | 2012-11-14 | 道淼科技(北京)有限公司 | Degradable drug loading stent |
-
2018
- 2018-04-28 CN CN201810396947.7A patent/CN108434535A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1589162A (en) * | 2000-10-24 | 2005-03-02 | 博士伦公司 | Prevention of bacterial attachment to biomaterials by cationic polysaccharides |
| CN102008751A (en) * | 2010-11-24 | 2011-04-13 | 北京道淼浩博科技发展有限公司 | Biodegradable stent composite material and preparation method thereof |
| CN102772831A (en) * | 2012-08-20 | 2012-11-14 | 道淼科技(北京)有限公司 | Degradable drug loading stent |
Non-Patent Citations (1)
| Title |
|---|
| 陈斌: "电化学法沉积水杨酸衍生物改善不锈钢表面生物性能的研究", 《上海大学博士学位论文》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10688190B2 (en) | Medication system | |
| US9827282B2 (en) | Medication dispensing system | |
| RU2616494C2 (en) | Nanoparticles carrying chemotherapeutic anti-cancer therapeutic agent | |
| CN101969934B (en) | Drug-containing nanoparticles | |
| CN103566414B (en) | A kind of nucleocapsid structure receives particulate coatings intravascular stent and preparation method thereof | |
| Santocildes-Romero et al. | Fabrication of electrospun mucoadhesive membranes for therapeutic applications in oral medicine | |
| US20180021438A1 (en) | Medication dispensing system | |
| US10675314B2 (en) | Medication dispensing system | |
| CN101756908A (en) | Hydroxyapatite micro-sphere with polyester coating and preparation method thereof | |
| CN103566415A (en) | Human body blood vessel implant with coatings on two surfaces and manufacturing method thereof | |
| AU2008252931B2 (en) | An extended-release composition comprising a somatostatin derivative in microparticles | |
| CN116350858B (en) | Drug-coated balloon catheter and preparation method thereof | |
| CN107106506A (en) | The injectable particulate that super localization for therapeutic agent discharges | |
| CN101711710B (en) | Medicament eluting stent and preparation method thereof | |
| CN108434535A (en) | A kind of preparation method inhibiting hyperblastosis type coating bracket material | |
| CN116350859B (en) | Drug-coated balloon catheter and preparation method thereof | |
| CN102949450B (en) | Nux vomica alkaloid patch for treating local myalgia and arthralgia and preparation method | |
| CN103565564A (en) | Double-side coated drug eluting stent containing magnetic bottom layer and manufacturing method thereof | |
| CN100366249C (en) | Control releasing administration system for temozolomide | |
| CN107496998A (en) | Periphery bracket for eluting medicament and its preparation and application | |
| CN108619581A (en) | The application of medication coat, interventional medical device and epiphysin in medication coat | |
| CN216169073U (en) | Double-channel targeted coating drug stent | |
| CN104324032B (en) | Antituberculotics three compound recipe microsphere vascular targeting thromboembolism slow releasing agent and its production and use | |
| CN112569206A (en) | Albumin nano drug delivery system with anti-tumor metastasis and targeting functions and preparation method thereof | |
| CN105709279B (en) | The preparation method of PLGA-S1P nano material and PLGA-S1P nano coating bracket |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180824 |